DAX ®12.686,29-0,62%TecDAX ®2.869,30-0,27%Dow Jones25.080,98-0,47%NASDAQ 1007.348,57-0,56%
finanztreff.de
WM Tippspiel
teilnehmen und gewinnen
finanztreff.de

DGAP-Adhoc: BB Biotech AG reports preliminary results for 1H 2018

| Quelle: Dow Jones Newswire Web | Lesedauer etwa 3 min. | Text vorlesen Stop Pause Fortsetzen
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning/Half Year Results
BB Biotech AG reports preliminary results for 1H 2018

12-Jul-2018 / 18:05 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Media Release, July 12, 2018

*BB Biotech AG reports preliminary results for 1H 2018*

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN
CH0038389992) is releasing the following information about its results for
the first half year of 2018.

Based on preliminary unaudited consolidated results, BB Biotech closed the
first half year of 2018 with a loss of around CHF 70 mn (CHF 478.4 mn profit
in the corresponding period of the previous year). As an investment company,
the result reflects the performance of the stocks it holds in its investment
portfolio.

BB Biotech's share price increased 8.4% in CHF and 8.2% in EUR during the
corresponding period.

The interim report as of June 30, 2018 will be published on July 20, 2018.

*For further information:*

*Investor Relations*
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
tel. +41 44 267 67 00
Dr. Silvia Schanz, ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch

*Media Relations*
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
tel. +41 44 267 67 07
Tanja Chicherio, tch@bellevue.ch

*www.bbbiotech.com [1]*

*Company profile*
BB Biotech invests in companies in the fast growing market of biotechnology
and is one of the world's largest investors in this sector. BB Biotech is
listed in Switzerland, Germany and Italy. Its investments are focused on
listed companies that are developing and commercializing novel medical
treatments and cures. BB Biotech's investment selection process is guided by
the fundamental research and analysis of physicians and molecular
biologists. Its Board of Directors has many years of experience in industry
and science.

12-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich,
Stuttgart; SIX

End of Announcement DGAP News Service

703867 12-Jul-2018 CET/CEST


1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=f80c4feec698b1c5fa8ce919781cfb2a&application_id=703867&site_id=vwd&application_name=news


(END) Dow Jones Newswires

July 12, 2018 12:05 ET ( 16:05 GMT)
Werbung

Passende Hebelprodukte von

WKN Bezeichnung Hebel
DM2KHC BB BIOTEC WaveUnlimited S 64.1624 (DBK) 6,290
Werbung

Das könnte Sie auch interessieren

Im Artikel erwähnt...

BB BIOTECH
BB BIOTECH - Performance (3 Monate) 58,76 -0,59%
EUR -0,35
Porträt - Chart - Kennzahlen - Firmenprofil
Nachrichten
18.07. Bb Biotech: Hoch bewertet?
17.07. Bb Biotech: Reagiert die Aktie?
16.07. BB Biotech: Warten auf den 20. Juli!
Werbung
Werbung

News-Suche

Suchbegriff:
Werbung

Aktuelle Videos

zur Mediathek
Werbung

Werbung
Börse Stuttgartschliessen
Börse Stuttgart

Gewinnen Sie pures Gold!

Unter allen Teilnehmern an der Anlegerumfrage verlost der Börse Stuttgart Anlegerclub Gold im Gesamtwert von über 1000 Euro.

Jetzt kostenlos anmelden und mitmachen!
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook, Google+ oder Twitter
Aktuelle Umfrageschliessen
Walmart hat ein Patent für Audioüberwachung im Kassenbereich erhalten. Was halten Sie davon?
Jetzt abstimmen!
Alle Umfragen ansehen
schliessen